GlassScriptPhysician profile
Jett E Mcguire
NPI 1942824339
$1,849.64
in general payments reported to CMS, 2019-2025
25 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $316 · 2023: $640 · 2024: $627 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.73 | 2021-2024 | |
| Lilly USA, LLC | $257.79 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $171.03 | 2023-2025 | |
| Insmed, INC. | $128.00 | 2025 | Arikayce |
| Novo Nordisk INC | $123.44 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $112.03 | 2021-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $101.48 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $81.01 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $68.59 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.10 | 2023-2024 | Trintellix |
| Exact Sciences Corporation | $52.27 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $51.41 | 2023 | |
| Glaxosmithkline, LLC. | $48.87 | 2023-2024 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $46.29 | 2021-2022 | |
| Philips North America LLC | $31.86 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.93 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $29.55 | 2023 | Rexulti |
| Astellas Pharma US INC | $23.98 | 2023 | Veozah |
| Impel Pharmaceuticals INC. | $23.65 | 2023 | Trudhesa |
| Merck Sharp & Dohme LLC | $21.46 | 2023 | Belsomra |
| Phathom Pharmaceuticals, INC. | $20.15 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.30 | 2022 | |
| Currax Pharmaceuticals LLC | $13.59 | 2023 | Contrave |
| Astrazeneca Pharmaceuticals LP | $13.13 | 2022 | |
| Phadia US INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jett Mcguire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.